We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic expos... Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Show more
Shareholders of Applied Therapeutics, Inc. Should Contact The Gross Law Firm Before February 18, 2025 to Discuss Your Rights - APLT PR Newswire NEW YORK, Dec. 30, 2024 NEW YORK, Dec. 30, 2024...
Lost Money on Applied Therapeutics, Inc.(APLT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, Dec. 26, 2024 NEW YORK, Dec. 26, 2024 /PRNewswire/...
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024...
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc...
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) should contact The Gross Law Firm about pending Class Action - APLT PR Newswire NEW YORK, Dec. 19, 2024 NEW YORK, Dec. 19, 2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0587 | -6.90344584264 | 0.8503 | 0.9 | 0.7726 | 5715262 | 0.86850411 | CS |
4 | -1.2584 | -61.3853658537 | 2.05 | 2.08 | 0.7726 | 10375737 | 1.26252343 | CS |
12 | -6.9584 | -89.7858064516 | 7.75 | 10.6237 | 0.7726 | 5470103 | 3.33891819 | CS |
26 | -3.8684 | -83.0128755365 | 4.66 | 10.6237 | 0.7726 | 3766128 | 4.55143591 | CS |
52 | -2.5584 | -76.3701492537 | 3.35 | 10.6237 | 0.7726 | 2662269 | 4.60857619 | CS |
156 | -7.9784 | -90.9737742303 | 8.77 | 10.6237 | 0.4995 | 1200927 | 3.90445384 | CS |
260 | -25.3484 | -96.9716908952 | 26.14 | 57.39 | 0.4995 | 777263 | 5.85109238 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions